Pay in 4 interest-free payments of $7.37 Learn more
Ships within 48 hours · Estimated delivery Sep 22 - Sep 27
The MR-base platform supports systematic causal inference across the human phenome
Results from the Phase II IMscin002 study showed that 71% of patients preferred Hybreza to the intravenous formulation
They will submit the PA request to Ambetter
Phase 3 TRIUMPH trial results The Phase 3 TRIUMPH-4 trial, announced in late 2025, confirmed and even improved on the Phase 2 numbers
Carey et al
US$ 26.02
US$ 20.72
US$ 19.99
US$ 28.25
US$ 28.64
US$ 23.17
